AbbVie | ABBV - Pre Tax Profit

Stock Price
209.41
Daily Change
-0.98 -0.47%
Monthly
2.80%
Yearly
12.76%
Q2 Forecast
206.16

AbbVie reported $5.57B in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Abbott USD 2.39B 27M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eisai JPY -7.94B 29.94B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
J&J USD 7.82B 2.86B Mar/2026
Medtronic USD 2.1B 224M Sep/2025
Merck USD 3.42B 3.32B Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026
Pacira USD 571K 8.95M Dec/2025
Perrigo USD -1.33B 1.35B Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
UCB EUR 789M 427M Jun/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
United Therapeutics USD 444M 6M Dec/2025
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Zoetis USD 761M 126M Dec/2025